Unlock stock picks and a broker-level newsfeed that powers Wall Street.
São Paulo - Delayed Quote BRL

Johnson & Johnson (JNJB34.SA)

Compare
62.20
-0.56
(-0.89%)
At close: March 14 at 5:10:00 PM GMT-3
Loading Chart for JNJB34.SA
  • Previous Close 62.76
  • Open 62.70
  • Bid 61.90 x --
  • Ask 62.23 x --
  • Day's Range 61.80 - 62.70
  • 52 Week Range 49.65 - 65.90
  • Volume 1,599
  • Avg. Volume 10,096
  • Market Cap (intraday) 2.276T
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) 27.77
  • EPS (TTM) 2.24
  • Earnings Date Apr 15, 2025
  • Forward Dividend & Yield 1.34 (2.16%)
  • Ex-Dividend Date Feb 17, 2025
  • 1y Target Est --

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

www.jnj.com

138,100

Full Time Employees

December 29

Fiscal Year Ends

Recent News: JNJB34.SA

View More

Performance Overview: JNJB34.SA

Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 .

YTD Return

JNJB34.SA
5.79%
S&P 500
4.13%

1-Year Return

JNJB34.SA
19.74%
S&P 500
9.48%

3-Year Return

JNJB34.SA
15.10%
S&P 500
35.13%

5-Year Return

JNJB34.SA
64.83%
S&P 500
108.00%

Compare To: JNJB34.SA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: JNJB34.SA

View More

Valuation Measures

As of 3/14/2025
  • Market Cap

    2.28T

  • Enterprise Value

    2.35T

  • Trailing P/E

    27.78

  • Forward P/E

    15.17

  • PEG Ratio (5yr expected)

    1.09

  • Price/Sales (ttm)

    4.40

  • Price/Book (mrq)

    5.42

  • Enterprise Value/Revenue

    4.55

  • Enterprise Value/EBITDA

    16.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.84%

  • Return on Assets (ttm)

    8.13%

  • Return on Equity (ttm)

    20.06%

  • Revenue (ttm)

    88.82B

  • Net Income Avi to Common (ttm)

    14.07B

  • Diluted EPS (ttm)

    2.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.52B

  • Total Debt/Equity (mrq)

    52.92%

  • Levered Free Cash Flow (ttm)

    16.67B

Research Analysis: JNJB34.SA

View More

People Also Watch